<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pharmacogenetics in Psychiatry: CYP2D6 and CYP2C19</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
        }
        header {
            background-color: #f2f2f2;
            padding: 20px;
            text-align: center;
        }
        nav ul {
            list-style: none;
            padding: 0;
        }
        nav ul li {
            display: inline;
            margin-right: 20px;
        }
        nav ul li a {
            text-decoration: none;
            color: #333;
        }
        main {
            padding: 20px;
        }
        section {
            margin-bottom: 40px;
        }
        h2, h3 {
            color: #0056b3;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin-bottom: 20px;
        }
        th, td {
            border: 1px solid #ddd;
            padding: 8px;
            text-align: left;
        }
        th {
            background-color: #f2f2f2;
        }
        footer {
            background-color: #f2f2f2;
            padding: 10px;
            text-align: center;
            font-size: 0.8em;
        }
        @media (max-width: 768px) {
            nav ul li {
                display: block;
                margin-bottom: 10px;
            }
            table {
                font-size: 0.9em;
            }
        }
    </style>
</head>
<body>
    <header>
        <h1>Pharmacogenetics in Psychiatry: CYP2D6 and CYP2C19</h1>
        <nav>
            <ul>
                <li><a href="#introduction">Introduction</a></li>
                <li><a href="#medications">Affected Medications</a></li>
                <li><a href="#phenotypes">Phenotypes and Their Impact</a></li>
                <li><a href="#recommendations">Dosing Recommendations</a></li>
                <li><a href="#resources">Resources</a></li>
            </ul>
        </nav>
    </header>
    <main>
        <section id="introduction">
            <h2>Introduction</h2>
            <p>The genes <strong>CYP2D6</strong> and <strong>CYP2C19</strong> play a crucial role in the metabolism of many psychiatric medications, including antidepressants and antipsychotics. Variations in these genes can lead to different phenotypes—Poor Metabolizer (PM), Intermediate Metabolizer (IM), Extensive Metabolizer (EM), Rapid Metabolizer (RM), and Ultrarapid Metabolizer (UM)—that affect how patients process these drugs, impacting treatment efficacy and safety.</p>
            <p>Pharmacogenetic testing for CYP2D6 and CYP2C19 allows clinicians to personalize medication choices and dosages, potentially improving patient outcomes and minimizing adverse effects.</p>
        </section>

        <section id="medications">
            <h2>Affected Medications</h2>
            <p>Below is a list of psychiatric medications metabolized by CYP2D6 and/or CYP2C19:</p>

            <h3>Antidepressants</h3>
            <table>
                <thead>
                    <tr>
                        <th>Medication</th>
                        <th>Primary Metabolizing Enzyme</th>
                        <th>Secondary Enzyme</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Fluvoxamine</td><td>CYP2D6</td><td>-</td></tr>
                    <tr><td>Paroxetine</td><td>CYP2D6</td><td>-</td></tr>
                    <tr><td>Citalopram</td><td>CYP2C19</td><td>CYP2D6</td></tr>
                    <tr><td>Escitalopram</td><td>CYP2C19</td><td>CYP2D6</td></tr>
                    <tr><td>Sertraline</td><td>CYP2C19</td><td>CYP2D6</td></tr>
                    <tr><td>Amitriptyline</td><td>CYP2D6, CYP2C19</td><td>-</td></tr>
                    <tr><td>Clomipramine</td><td>CYP2D6, CYP2C19</td><td>-</td></tr>
                    <tr><td>Doxepin</td><td>CYP2D6, CYP2C19</td><td>-</td></tr>
                    <tr><td>Imipramine</td><td>CYP2D6, CYP2C19</td><td>-</td></tr>
                    <tr><td>Trimipramine</td><td>CYP2D6, CYP2C19</td><td>-</td></tr>
                    <tr><td>Nortriptyline</td><td>CYP2D6</td><td>-</td></tr>
                    <tr><td>Desipramine</td><td>CYP2D6</td><td>-</td></tr>
                </tbody>
            </table>

            <h3>Antipsychotics</h3>
            <table>
                <thead>
                    <tr>
                        <th>Medication</th>
                        <th>Primary Metabolizing Enzyme</th>
                        <th>Secondary Enzyme</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Haloperidol</td><td>CYP2D6</td><td>-</td></tr>
                    <tr><td>Chlorpromazine</td><td>CYP2D6</td><td>-</td></tr>
                    <tr><td>Thioridazine</td><td>CYP2D6</td><td>-</td></tr>
                    <tr><td>Perphenazine</td><td>CYP2D6</td><td>-</td></tr>
                    <tr><td>Risperidone</td><td>CYP2D6</td><td>CYP3A4</td></tr>
                    <tr><td>Aripiprazole</td><td>CYP2D6, CYP3A4</td><td>-</td></tr>
                    <tr><td>Brexpiprazole</td><td>CYP2D6, CYP3A4</td><td>-</td></tr>
                    <tr><td>Olanzapine</td><td>CYP1A2</td><td>CYP2D6</td></tr>
                    <tr><td>Clozapine</td><td>CYP1A2</td><td>CYP2C19, CYP2D6, CYP3A4</td></tr>
                </tbody>
            </table>
        </section>

        <section id="phenotypes">
            <h2>Phenotypes and Their Impact</h2>
            <p>The phenotypes for CYP2D6 and CYP2C19 are categorized as follows:</p>

            <h3>CYP2D6 Phenotypes</h3>
            <table>
                <thead>
                    <tr>
                        <th>Phenotype</th>
                        <th>Activity Score</th>
                        <th>Impact on Drug Metabolism</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Poor Metabolizer (PM)</td>
                        <td>0</td>
                        <td>No or significantly reduced enzyme activity; higher drug levels, increased risk of side effects.</td>
                    </tr>
                    <tr>
                        <td>Intermediate Metabolizer (IM)</td>
                        <td>0.5 or 1</td>
                        <td>Reduced enzyme activity; may require dose adjustments.</td>
                    </tr>
                    <tr>
                        <td>Extensive Metabolizer (EM)</td>
                        <td>1.5 or 2</td>
                        <td>Normal enzyme activity; standard dosing applies.</td>
                    </tr>
                    <tr>
                        <td>Ultrarapid Metabolizer (UM)</td>
                        <td>>2</td>
                        <td>Increased enzyme activity; lower drug levels, may require higher doses.</td>
                    </tr>
                </tbody>
            </table>

            <h3>CYP2C19 Phenotypes</h3>
            <table>
                <thead>
                    <tr>
                        <th>Phenotype</th>
                        <th>Alleles</th>
                        <th>Impact on Drug Metabolism</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Poor Metabolizer (PM)</td>
                        <td>No functional alleles (e.g., *2/*2)</td>
                        <td>Significantly reduced enzyme activity; higher drug levels, increased risk of side effects.</td>
                    </tr>
                    <tr>
                        <td>Intermediate Metabolizer (IM)</td>
                        <td>One functional allele (e.g., *1/*2)</td>
                        <td>Reduced enzyme activity; may require dose adjustments.</td>
                    </tr>
                    <tr>
                        <td>Extensive Metabolizer (EM)</td>
                        <td>Two functional alleles (*1/*1)</td>
                        <td>Normal enzyme activity; standard dosing applies.</td>
                    </tr>
                    <tr>
                        <td>Rapid Metabolizer (RM)</td>
                        <td>One *17 allele (e.g., *1/*17)</td>
                        <td>Increased enzyme activity; may require higher doses.</td>
                    </tr>
                    <tr>
                        <td>Ultrarapid Metabolizer (UM)</td>
                        <td>Two *17 alleles (*17/*17)</td>
                        <td>Significantly increased enzyme activity; lower drug levels, may require higher doses.</td>
                    </tr>
                </tbody>
            </table>
        </section>

        <section id="recommendations">
            <h2>Dosing Recommendations</h2>
            <p>The <strong>Clinical Pharmacogenetics Implementation Consortium (CPIC)</strong> and the <strong>Dutch Pharmacogenetics Working Group (DPWG)</strong> provide guidelines for adjusting medication doses based on CYP2D6 and CYP2C19 phenotypes. Key recommendations include:</p>

            <h3>Antidepressants</h3>
            <ul>
                <li><strong>SSRIs (e.g., Citalopram, Escitalopram, Sertraline) - CYP2C19:</strong>
                    <ul>
                        <li>PM: Reduce dose by 50% or select an alternative drug.</li>
                        <li>IM: Consider dose reduction or alternative drug.</li>
                        <li>UM: May require higher doses or alternative drug.</li>
                    </ul>
                </li>
                <li><strong>Tricyclic Antidepressants (e.g., Amitriptyline, Nortriptyline) - CYP2D6 and CYP2C19:</strong>
                    <ul>
                        <li>PM for CYP2D6: Reduce dose or select alternative drug.</li>
                        <li>UM for CYP2D6: May require higher doses.</li>
                        <li>PM for CYP2C19: Consider dose adjustments.</li>
                    </ul>
                </li>
            </ul>

            <h3>Antipsychotics</h3>
            <ul>
                <li><strong>Risperidone - CYP2D6:</strong>
                    <ul>
                        <li>PM: Reduce dose or select alternative drug.</li>
                        <li>UM: May require higher doses.</li>
                    </ul>
                </li>
                <li><strong>Aripiprazole - CYP2D6:</strong>
                    <ul>
                        <li>PM: Reduce dose.</li>
                        <li>UM: May require higher doses.</li>
                    </ul>
                </li>
            </ul>
            <p>For detailed guidelines, refer to the <a href="https://cpicpgx.org/guidelines/">CPIC Guidelines</a> and <a href="https://www.knmp.nl/dossiers/farmacogenetica">DPWG Guidelines</a>.</p>
        </section>

        <section id="resources">
            <h2>Resources</h2>
            <p>For more information, visit these resources:</p>
            <ul>
                <li><a href="https://cpicpgx.org/guidelines/">CPIC Guidelines</a></li>
                <li><a href="https://www.knmp.nl/dossiers/farmacogenetica">DPWG Guidelines</a></li>
                <li><a href="https://www.pharmgkb.org/">PharmGKB</a></li>
            </ul>
        </section>
    </main>
    <footer>
        <p>Disclaimer: This website is for informational purposes only and should not be considered medical advice. Always consult a qualified healthcare provider before making changes to medication regimens.</p>
    </footer>
</body>
</html>
